Recombinant Human CTAG1B 293 Cell Lysate

• Cat.No.: CTAG1B-7218HCL

Specification

• Description: Antigen standard for cancer/testis antigen 1B (CTAG1B) is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.
• Tag: Non

Gene Information

• Gene Name: CTAG1B cancer/testis antigen 1B [ Homo sapiens ]
• Official Symbol: CTAG1B
• Synonyms: CTAG1B; cancer/testis antigen 1B; cancer/testis antigen 1 , CTAG, CTAG1; cancer/testis antigen 1; CT6.1; ESO1; LAGE2A; LAGE2B; NY ESO 1; cancer antigen 3; cancer/testis antigen 6.1; l antigen family member 2; New York esophageal squamous cell carcinoma 1; autoimmunogenic cancer/testis antigen NY-ESO-1; CTAG; CTAG1; CTAG1A; LAGE-2; NY-ESO-1
• Gene ID: 1485
• mRNA Refseq: NM_001327
• Protein Refseq: NP_001318
• MIM: 300156
• UniProt ID: P78358
• Chromosome Location: Xq28

Reviews

02/22/2023

The Aldehyde Protein exhibits an exceptional level of quality that surpasses my experimental requirements.

03/02/2022

Its impeccable purity and consistency have consistently delivered accurate and robust results, enabling me to make significant strides in my research.

10/22/2016

One remarkable aspect of the CTAG1B Protein is the outstanding technical support provided by the manufacturer.

Q&As

How does CTAG1B contribute to the development of personalized cancer treatments?

CTAG1B expression profiling can help in tailoring personalized cancer treatments by identifying patients who may benefit from specific immunotherapeutic approaches.

How is the expression of CTAG1B in cancer cells significant for clinical applications?

The expression of CTAG1B in cancer cells is significant as it can serve as a potential biomarker for cancer diagnosis and prognosis.

In which cancers is CTAG1B protein commonly expressed?

CTAG1B expression is commonly observed in a variety of cancers, including melanoma, lung cancer, and bladder cancer.

Are there any specific diagnostic tests that utilize CTAG1B protein as a biomarker?

Yes, some diagnostic tests, such as immunohistochemistry (IHC), may use CTAG1B protein expression to aid in cancer diagnosis.

Can monitoring CTAG1B levels be useful during cancer treatment?

Yes, monitoring CTAG1B levels during cancer treatment can provide valuable information about the effectiveness of the therapy and potential relapse risks.